New Leadership Team For European Biosimilars Group
This article was originally published in Scrip
The European Biosimilar medicines Group (EBG), part of the European Generic and Biosimilar Medicines Association (EGA), has appointed a new leadership team, with Carol Lynch chairing the overall group and Klaus Martin heading up the EBG's market access group. Lynch, who is global head of biopharmaceuticals and oncology injectables at Sandoz, previously held commercial and development leadership positions at Novartis Pharmaceuticals. Martin is senior director and chief science officer at Polpharma Biologics, leading global late-stage development, portfolio management and strategic marketing and medical affairs, and has worked in the biosimilars area since 2002. Ildiko Aradi of Gedeon Richter and Karl Heinz Emmert of Teva were re-elected vice-chairs of the EBG, while Dan Ionesco of Sandoz was appointed vice-chair of the market access group.